Management

 

Dr. Sven Wichert – CEO

Dr. Wichert is one of the founders of Systasy Bioscience. He was appointed CEO in 2012, and he has been involved in the foundation process of Systasy Bioscience since 2010. Since 2011, he has been heading the “EXIST-Forschungstransfer” program.

Dr. Sven Wichert obtained his degree from the University of Heidelberg in 2009 for the analysis of complex datasets linking myelination and transcriptomics. During his PhD he gained in-depth experience as bioinformatician on the analysis of high-throughput datasets and the development of the EXTassay technology.

Dr. Wichert is specialized in EXTassay design and analysis, and general laboratory automation processes.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Michael Wehr – CSO

Dr. Wehr is one of the founders of Systasy Bioscience. He was appointed CSO in 2012, and he has been involved in the foundation process of Systasy Bioscience since 2010. He is heading the section Research & Development to develop, validate, and implement standard procedures for cell-based assays including EXTassay integration.

Prior to this appointment, Dr. Wehr spent four years at the flagship institute of Cancer Research UK, the London Research Institute, to perform cell-based RNAi screens to identify new players implicated in cancer. He obtained his degree from the University of Heidelberg in 2006 for developing the splitSENSOR technique to monitor regulated protein-protein interactions and dynamic receptor activities in living cells.  

Dr. Wehr is specialized in cell-based assays, assay development, pathway profiling analyses and high-throughput screening approaches.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Ben Brankatschk – CTO

Dr. Brankatschk was appointed CTO in 2013. He is heading the EXTassay Unit to optimize technical and integrative features of multi-parametric assays. Prior to this appointment, he joined Systasy Bioscience as scientist for EXTassay development.

Dr. Brankatschk obtained his PhD from the University of Geneva in 2010 for establishing new concepts of EGF receptor signaling and trafficking using microarrays and the NanoString technology.

Dr. Brankatschk is specialized in analyzing large-scale transcriptomic data sets, next-generation sequencing, and pathway profiling analyses.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Alexander Pieper – Business Advisor

Dr. Pieper was appointed Business Advisor in 2014. Further, he was involved in the initial stages of the foundation process and regularly served as contact for economical and administrative questions.

Prior to this appointment, Dr. Pieper gained extensive experience within the area of personalized healthcare working as global project manager for Targos, a leader for customer-oriented global biomarker services. Currently, he is working as Medical Science Manager for a big pharmaceutical company within the area of immuno-oncology. He obtained his PhD from the University of Göttingen for the description of a new transcription factor regulating axonal growth. In addition, he obtained the degree of a certified executive manager from the Hagener Institute of Management Studies (HIMS).

Dr. Pieper is specialized in questions related to business execution and project management, and provides a broad network of contacts within the pharmaceutical industry to the company.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Contact us

Systasy Bioscience GmbH
Adams-Lehmann-Strasse 56
80797 Munich - Germany
+49 89 2155 3085
info@systasy.de

Business Hours

Our support Hotline is available:
+49 89 2155 3085

  • Monday-Friday: 9am to 5pm
  • Saturday & Sunday: closed